natgillin/translations-raw huggingface dataset:
procainamide, quinidine, sotalol, dofetilide, ibutilide, amiodarone or dronedarone; - medicines to treat bacterial infections (by mouth: clarithromycin, moxifloxacin; via injection: 
prokainamid, kinidin, sotalol, dofetilid, ibutilid, amiodaron ili dronedaron; - lijekove koji liječe bakterijske infekcije (kroz usta: klaritromicin, moksifloksacin; putem injekcije: eritromicin, pentamidin); - lijekove koji liječe gljivične infekcije (ketokonazol, osim u šamponu); - lijekove koji liječe određene psihijatrijske poremećaje (klorpromazin, tioridazin, flufenazin,
Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate). 
Signifor 60 mg: svaka bočica sadrži 60 mg pasireotida (u obliku pasireotidpamoata).
Asymptomatic elevations in lipase and amylase were observed in patients receiving pasireotide in clinical studies. 
U bolesnika koji su primali pasireotid u kliničkim ispitivanjima bila su uočena asimptomatska povišenja lipaze i amilaze.
Signifor 30 mg: each vial contains 30 mg pasireotide (as pasireotide pamoate). 
Signifor 30 mg: svaka bočica sadrži 30 mg pasireotida (u obliku pasireotidpamoata).
Compound hsst1 
Spoj hsst1
Signifor 20 mg is available in unit packs containing one vial of powder with 20 mg pasireotide and one pre-filled syringe with 2 ml solvent. 
Signifor 20 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 20 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
Signifor 10 mg: each vial contains 10 mg pasireotide (as pasireotide pamoate). 
Signifor 10 mg: svaka bočica sadrži 10 mg pasireotida (u obliku pasireotidpamoata).
- medicines to treat certain psychiatric disorders (chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol, tiapride, amisulpride, sertindole, methadone); - medicines to treat hay fever and other allergies (terfenadine, astemizole, mizolastine); - medicines used in the prevention or treatment of malaria (chloroquine, halofantrine, lumefantrine); - medicines to control blood pressure such as: 
- lijekove koji liječe nepravilne otkucaje srca, kao što su lijekovi koji sadrže dizopiramid, prokainamid, kinidin, sotalol, dofetilid, ibutilid, amiodaron ili dronedaron; - lijekove koji liječe bakterijske infekcije (kroz usta: klaritromicin, moksifloksacin; putem injekcije: eritromicin, pentamidin); - lijekove koji liječe gljivične infekcije (ketokonazol, osim u šamponu); - lijekove koji liječe određene psihijatrijske poremećaje (klorpromazin, tioridazin, flufenazin, pimozid, haloperidol, tiaprid, amisulpirid, sertindol, metadon); - lijekove koji liječe peludnu groznicu i druge alergije (terfenadin, astemizol, mizolastin); - lijekove koji se koriste u sprečavanju ili liječenju malarije (klorokin, halofantrin, lumefantrin); - lijekove za kontroliranje krvnog tlaka, kao što su:
One vial contains 20 mg pasireotide (as pasireotide pamoate). 
Jedna bočica sadrži 20 mg pasireotida (u obliku pasireotidpamoata).
Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). 
Signifor 40 mg: svaka bočica sadrži 40 mg pasireotida (u obliku pasireotidpamoata).
Signifor 60 mg powder and solvent for suspension for injection One vial contains 60 mg pasireotide (as pasireotide pamoate). 
Signifor 60 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 60 mg pasireotida (u obliku pasireotidpamoata).
Signifor 40 mg powder and solvent for suspension for injection EU/1/12/753/014-015 
Signifor 40 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/014-015
Signifor 0.9 mg: One ampoule of 1 ml solution contains 0.9 mg pasireotide (as pasireotide diaspartate). 
Signifor 0,9 mg: Jedna ampula s 1 ml otopine sadrži 0,9 mg pasireotida (u obliku pasireotiddiaspartata).
One vial contains 60 mg pasireotide (as pasireotide pamoate). 
Jedna bočica sadrži 60 mg pasireotida (u obliku pasireotidpamoata).
Pasireotide 
Doziranje
Signifor 10 mg is available in unit packs containing one vial of powder with 10 mg pasireotide and one pre filled syringe with 2 ml solvent. 
Signifor 10 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 10 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
1 ml solution for injection contains 0.9 mg pasireotide (as pasireotide diaspartate). 
1 ml otopine za injekciju sadrži 0,9 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 40 mg powder and solvent for suspension for injection One vial contains 40 mg pasireotide (as pasireotide pamoate). 
Signifor 40 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 40 mg pasireotida (u obliku pasireotidpamoata).
Signifor 10 mg powder and solvent for suspension for injection One vial contains 10 mg pasireotide (as pasireotide pamoate). 
Signifor 10 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 10 mg pasireotida (u obliku pasireotidpamoata).
Signifor 10 mg powder and solvent for suspension for injection EU/1/12/753/018 
Signifor 10 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/018
Signifor 0.6 mg: One ampoule of 1 ml solution contains 0.6 mg pasireotide (as pasireotide diaspartate). 
Signifor 0,6 mg: Jedna ampula s 1 ml otopine sadrži 0,6 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 30 mg is available in unit packs containing one vial of powder with 30 mg pasireotide and one pre filled syringe with 2 ml solvent. 
Signifor 30 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 30 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
Signifor 30 mg powder and solvent for suspension for injection One vial contains 30 mg pasireotide (as pasireotide pamoate). 
Signifor 30 mg prašak i otapalo za suspenziju za injekciju Jedna bočica sadrži 30 mg pasireotida (u obliku pasireotidpamoata).
Signifor 60 mg is available in unit packs containing one vial of powder with 60 mg pasireotide and one pre-filled syringe with 2 ml solvent. 
Signifor 60 mg dostupan je u jediničnim pakiranjima koja sadrže jednu bočicu praška s 60 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
1 ml solution for injection contains 0.6 mg pasireotide (as pasireotide diaspartate). 
1 ml otopine za injekciju sadrži 0,6 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 40 mg is available in unit packs containing one vial of powder with 40 mg pasireotide and one pre-filled syringe with 2 ml solvent. 
Signifor 40 mg je dostupan u jediničnim pakiranjima koja sadrže jednu bočicu praška s 40 mg pasireotida i jednu napunjenu štrcaljku s 2 ml otapala.
congestive heart failure, unstable angina or clinically significant bradycardia. 
- s nekontroliranom ili značajnom bolesti srca, kongestivnim zatajenjem srca, nestabilnom anginom ili klinički značajnom bradikardijom. - koji uzimaju antiaritmike ili druge tvari za koje se zna da dovode do produženja QT intervala
Signifor 0.9 mg injection pasireotide 
Signifor 0,9 mg otopina za injekciju pasireotid
One vial contains 10 mg pasireotide (as pasireotide pamoate). 
Jedna bočica sadrži 10 mg pasireotida (u obliku pasireotidpamoata).
One vial contains 30 mg pasireotide (as pasireotide pamoate). 
Jedna bočica sadrži 30 mg pasireotida (u obliku pasireotidpamoata).
Signifor 20 mg powder and solvent for suspension for injection EU/1/12/753/013 
Signifor 20 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/013
“prolongation of the QT interval”, or “QT prolongation”; - low levels of potassium or magnesium in your blood; - gallstones; - or if you are taking anticoagulants (medicines used to reduce the clotting ability of the blood), 
(obično se osjeća kao pritisak, težina, stezanje, stiskanje ili bol u grudnom košu), - poremećaj srčanog ritma, kao što su nepravilni otkucaji srca ili abnormalni električni signal koji se zove “produženje QT intervala”, ili “QT produženje”, - niske razine kalija ili magnezija u krvi, - žučne kamence, - ili ako uzimate antikoagulanse (lijekove koji se koriste za smanjivanje sposobnosti zgrušavanja krvi), liječnik će Vam pratiti parametre koagulacije i možda prilagoditi dozu antikoagulansa.
Signifor 0.6 mg injection pasireotide 
Signifor 0,6 mg otopina za injekciju pasireotid
Signifor 0.3 mg: One ampoule of 1 ml solution contains 0.3 mg pasireotide (as pasireotide diaspartate). 
Signifor 0,3 mg: Jedna ampula s 1 ml otopine sadrži 0,3 mg pasireotida (u obliku pasireotiddiaspartata).
Injection site reaction, fatigue 
Reakcije na mjestu primjene, umor
Injection sites angle 
Mjesta primjene kut od
One vial contains 40 mg pasireotide (as pasireotide pamoate). 
Jedna bočica sadrži 40 mg pasireotida (u obliku pasireotidpamoata).
Signifor 0.3 mg injection pasireotide 
Signifor 0,3 mg otopina za injekciju pasireotid
Signifor 30 mg powder and solvent for suspension for injection EU/1/12/753/019 
Signifor 30 mg prašak i otapalo za suspenziju za injekciju EU/1/12/753/019
Switch from subcutaneous to intramuscular formulation in Cushing's disease There are no clinical data available on switching from the subcutaneous to the intramuscular pasireotide formulation. 
Ne postoje dostupni klinički podaci o prelasku sa supkutane na intramuskularnu formulaciju pasireotida.
Signifor 20 mg powder and solvent for suspension for injection pasireotide 
Signifor 20 mg prašak i otapalo za suspenziju za injekciju pasireotid
1 ml solution for injection contains 0.3 mg pasireotide (as pasireotide diaspartate). 
1 ml otopine za injekciju sadrži 0,3 mg pasireotida (u obliku pasireotiddiaspartata).
Signifor 60 mg powder and solvent for suspension for injection pasireotide 
Signifor 60 mg prašak i otapalo za suspenziju za injekciju pasireotid
Signifor 10 mg powder and solvent for suspension for injection pasireotide 
Signifor 10 mg prašak i otapalo za suspenziju za injekciju pasireotid
Month 6 
Dublin 4
Signifor 40 mg powder and solvent for suspension for injection pasireotide 
Signifor 40 mg prašak i otapalo za suspenziju za injekciju pasireotid
Signifor 30 mg powder and solvent for suspension for injection pasireotide 
Signifor 30 mg prašak i otapalo za suspenziju za injekciju pasireotid
Signifor 20 mg powder for injection pasireotide 
Signifor 20 mg prašak za injekciju pasireotid i.m.
Signifor 10 mg powder for injection pasireotide 
Signifor 10 mg prašak za injekciju pasireotid i.m.
Signifor 30 mg powder for injection pasireotide 
Signifor 30 mg prašak za injekciju pasireotid i.m.
Common 
Physical
Signifor 40 mg powder for injection pasireotide 
Signifor 40 mg prašak za injekciju pasireotid i.m.
Signifor 60 mg powder for injection pasireotide 
Signifor 60 mg prašak za injekciju pasireotid i.m.
Fatigue* 
Umor*
• metformin, liraglutide, vildagliptin, nateglinide (antidiabetic medicines); - medicines to treat irregular heartbeat, such as medicines containing disopyramide, 
• metformin, liraglutid, vildagliptin, nateglinid (antidijabetici),
Octreotide 
FARMACEUTSKI
Pituitary hormones 
Hormoni hipofize
Multipack: 30 (5 packs of 6) ampoules. 
Otopina za injekciju višestruko pakiranje: 18 (3 pakiranja po 6) ampula. višestruko pakiranje: 30 (5 pakiranja po 6) ampula. višestruko pakiranje: 60 (10 pakiranja po 6) ampula.
25 mg Powder for solution for injection 
25 mg Prašak za otopinu za injekciju
Subcutaneous use vial (glass) 
Napunjena štrcaljka (staklo)
24 vials + 24 prefilled syringes + 24 needles + 24 vial adaptors + 48 swabs 
4 bočice + 4 napunjene štrcaljke + 4 igle + 4 nastavka za bočice + 8 jastučića
4 vials + 8 swabs 
4 bočice + 8 jastučića
Section 4.8. 
Dio 4.8.
Adopted at the 11-14 April 2016 PRAC 
Usvojeno na sjednici PRAC-a 11.-14. travnja 2016.
Olanzapine - Drug reaction with eosinophilia and systemic symptoms (DRESS)(EPITT no 18534) 
Olanzapin - Reakcija na lijek s eozinofilijom i sistemskim simptomima (DRESS) (EPITT br. 18534)
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (frequency unknown) 
Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) (učestalost nepoznata)
They shall be removed or replaced by accurate medical terms. 
One će biti uklonjene ili zamijenjene točnim medicinskim pojmovima.
The PRAC adopted a recommendation on 16 October 2018 which was then considered by the CHMP, in accordance with Article 107k of Directive 2001/83/EC. 
PRAC je 16. listopada 2018. prihvatio preporuku koju je zatim razmatrao CHMP u skladu s člankom 107. k Direktive 2001/83/EZ.
Thus, the indication septicaemia should be deleted. 
Prema tome, indikaciju septikemije treba izbrisati.
These indications shall be amended. 
Te će indikacije biti izmijenjene.
The PRAC also reviewed all data submitted by different stakeholders, both before and after, the public hearing. 
PRAC je također pregledao sve podatke koje su različiti dionici dostavili prije i poslije javne rasprave.
(Fluoro)quinolones have been approved in the EU for a diversity of indications - over one hundred indications of various granularities. 
(Fluoro)kinoloni odobreni su u EU-u za raznovrsne indikacije - više od stotinu indikacija različitih razina razrađenosti.
(2) or the terminology is incorrect from a medical perspective. 
(2) ili je iz medicinske perspektive njihova terminologija netočna.
There is no avalaible data establishing efficacy in this clinical setting. 
Nema dostupnih podataka koji bi ustanovili djelotvornost u ovom kliničkom okruženju.
Based on the review of available scientific data, cases of uncomplicated cystitis have been often described as self-limiting. 
Na temelju pregleda dostupnih znanstvenih podataka, slučajevi nekompliciranog cistitisa često su opisani kao samoograničavajući.
The recommendation for the restriction to last line is based on the below: 
Preporuka za ograničenje na posljednju liniju liječenja temelji se na sljedećem:
It is also noted that these substances are not mentioned in any clinical guidelines and their place in the therapeutic armamentarium of urinary / genital / gastro-intestinal infections is not justified anymore. 
Također je napomenuto da se te tvari ne spominju ni u jednoj kliničkoj smjernici i njihovo mjesto u terapijskom armamentariju urinarnih/genitalnih/gastrointestinalnih infekcija više nije opravdano.
• Category 4: The Indications are considered too broad in view of the evidence available and related to some (sub) indications mentioned in categories 1, 2 or 3 above. 
• 4. kategorija: Indikacije se smatraju preopširnima s obzirom na dokaze koji su dostupni i koji se odnose na neke (pod)indikacije spomenute prethodno u 1., 2. ili 3. kategoriji.
Most cases of travellers' diarrhoea are self-limiting and resolve spontaneously within 3-5 days. 
U većini slučajeva putnički je proljev samoograničavajući i povlači se spontano unutar 3 do 5 dana.
Therefore these broad indications need to be amended. 
Stoga je te preopširne indikacije potrebno izmijeniti.
Overall, septicaemia is non-specific and is generally a secondary condition (a consequence) to a primary infection. 
Ukupno gledano, septikemija je nespecifična i u pravilu sekundarno stanje (posljedica) primarne infekcije.
• The PRAC concluded that in case of milder infections, other treatment options should be considered. 
• PRAC je zaključio da u slučaju blažih infekcija u obzir treba uzeti druge mogućnosti liječenja.
According to the European Association of Urology (EAU) guideline (Bonkat et al 2017), prevention of uncomplicated rUTIs includes counselling and behavioural modifications. 
Prema smjernicama Europskog udruženja za urologiju (European Association of Urology, EAU) (Bonkat et al 2017), prevencija nekomplicirane rekurentne infekcije urinarnog trakta uključuje savjetovanje i promjene u ponašanju.
Other indications were found to be incorrectly formulated in medical terms. 
Za ostale je indikacije ustanovljeno da nisu ispravno formulirane u smislu medicinskih pojmova.
In cases with Candida present on microscopy or culture, antifungals must be tried first, in order to see if other treatment is still needed. 
Kada je u mikroskopskom nalazu ili kulturi prisutna kandida, najprije treba pokušati s antimikoticima kako bi se vidjelo hoće li i dalje biti potrebno drugo liječenje.
Details of the amendments/ rewording of category 4 indications mentioned in tables 4 and 5 above are provided in Annex III of the CHMP opinion. 
Pojedinosti izmjena/promjena teksta indikacija 4. kategorije spomenutih u tablicama 4 i 5 u prethodnom tekstu, nalaze se u Prilogu III. mišljenja CHMP-a.
Urethritis and cervicitis 
Uretritis i cervicitis
In addition, the PRAC considered the views of patient organisations, patients, families and carers, and the views of healthcare professionals in a public hearing. 
Osim toga, PRAC je na javnoj raspravi razmotrio stajališta organizacija bolesnika, bolesnika, obitelji i skrbnika, i mišljenja zdravstvenih radnika.
• Acute and chronic prostatitis, including severe forms 
• Akutni i kronični prostatitis, uključujući teške oblike
Vaginal rinsing with povidone iodine can provide rapid relieve of symptoms but does not provide long-term cure of the bacterial loads. 
Vaginalno ispiranje jodiranim povidonom može dovesti do brzog ublažavanja simptoma, ali ne omogućava dugoročno izlječenje bakterijskog opterećenja.
Therefore, PRAC concluded that these indications should be maintained. 
Stoga je PRAC zaključio da te indikacije treba zadržati.
According to the current evidence and in line with the European guidelines (Woodhead et al. 2005, 2011), there is a modest benefit in using antibiotics for acute bronchitis in otherwise healthy individuals. 
Prema postojećim dokazima i u skladu s europskim smjernicama (Woodhead i dr. 2005., 2011.), primjena antibiotika za liječenje akutnog bronhitisa u inače zdravih osoba od male je koristi.
Pneumonia due to Gram-negative bacteria 
Pneumonija zbog gram-negativnih bakterija
Table 4 - Category 4 indications that are considered too broad 
Tablica 4 - indikacije 4. kategorije koje se smatraju preširokim
After review of the available data, mainly based on animal models (Giamarellou H et al. 1989), efficacy of pefloxacin cannot be established. 
Nakon pregleda dostupnih podataka, dobivenih većinom na životinjskim modelima (Giamarellou H i dr. 1989.), nije moguće ustanoviti djelotvornost pefloksacina.
Category 4: rewording of indications according to the current medical knowledge 
4. kategorija: promjena teksta indikacije u skladu sa sadašnjim medicinskim saznanjima
Indication 
Indikacije
In the EU, the indication endocarditis is approved exclusively for pefloxacin. 
U EU-u indikacija endokarditisa odobrena je isključivo za pefloksacin.
Based on the available data, approximately 90% cases of pharyngitis and 70% cases of tonsillitis in adults and children are of viral origin (Zoorob et al 2012). 
Na temelju dostupnih podataka, približno 90 % slučajeva faringitisa i 70 % slučajeva tonzilitisa u odraslih i djece virusnog su podrijetla (Zoorob i dr., 2012.).
The recent study by Gágyor et al (2015) showed that two thirds of women with uncomplicated urinary tract infection treated with ibuprofen recovered without any antibiotics. 
Novije ispitivanje koje je proveo Gágyor i dr. (2015.) pokazalo je da se dvije trećine žena s nekompliciranom infekcijom urinarnog trakta koja je bila liječena ibuprofenom, oporavilo bez primjene antibiotika.
Furthermore, the terminology ‘Infection of cerebrospinal fluid' is considered by the PRAC to be incorrect from a medical perspective. 
Nadalje, PRAC smatra da je termin „infekcija cerebrospinalne tekućine” netočan iz medicinske perspektive.
Risk factors associated with appearance of the assessed ADRs remain one of the main uncertainties and further examination of the risk factors should be further explored. 
Čimbenici rizika povezani s pojavom procijenjenih nuspojava ostaju jedna od glavnih nesigurnosti pa je potrebno njihovo daljnje istraživanje.
Category 2: indications to be restricted 
2. kategorija: indikacije koje treba ograničiti
Indeed, the PRAC could not identify any solid evidence on the efficacy of (fluoro)quinolone use in this indication. 
PRAC zapravo nije mogao ustanoviti nijedan čvrst dokaz o djelotvornosti primjene (fluoro)kinolona u toj indikaciji.
Indications in this category are amended (please refer to Annex III) as they are either: 
U ovoj kategoriji izmijenjen je tekst indikacija (pogledajte Prilog III.) jer su one:
It should be noted that pefloxacin has a poor antimicrobial activity against P. aeruginosa, thus, the benefit is very limited. 
Valja napomenuti da pefloksacin ima slabo antimikrobno djelovanje protiv P. aeruginosa, prema tome, korist je vrlo ograničena.
Indeed, due to their chemical structure and the related pharmacodynamic and pharmacokinetic profile (very narrow range of antibacterial activity, high minimal inhibitory concentrations) their benefit is limited based on the current available data. 
Zbog njihove kemijske strukture i s njom povezanog farmakodinamičkog i farmakokinetičkog profila (vrlo uzak raspon antibakterijskog djelovanja, visoke minimalne inhibitorne koncentracije), njihova je korist na temelju trenutačno dostupnih podataka ograničena.
While these ADRs are already included in the EU product information of quinolones and fluoroquinolones, the severity and persistence of these known ADRs has not yet been systematically evaluated in the EU. 
Iako su na području EU-a te nuspojave već uključene u informacije o lijekovima za kinolone i fluorokinolone, težina i ustrajnost tih poznatih nuspojava još nije sustavno procijenjena u EU-u.
Inappropriate use of (fluoro)quinolones is associated with rapidly increasing bacterial resistance to these agents (Committee on Infectious Diseases 2006; Murray and Baltimore 2007). 
Neodgovarajuća primjena (fluoro)kinolona povezana je s rezistencijom bakterija na te lijekove koja se brzo povećava (Committee on Infectious Diseases 2006; Murray and Baltimore 2007).
• The Pharmacovigilance Risk Assessment Committee (PRAC) considered the procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data for medicinal products containing substances related to quinolones and fluoroquinolones for systemic and inhaled use. 
• Odbor za procjenu rizika u području farmakovigilancije (PRAC) razmotrio je postupak u skladu s člankom 31. Direktive 2001/83/EZ pokrenut na temelju farmakovigilancijskih podataka za lijekove koji sadrže tvari povezane s kinolonima i fluorokinolonima za sistemsku primjenu i inhalaciju.
About 80% cases of rhinosinusitis occurring in clinical practice are of viral origin and only a negligible proportion of these cases (i.e. 0,5-2%) develop to bacterial infection (Gwaltney 1996). 
Oko 80 % slučajeva rinosinusitisa, koji se pojave u kliničkoj praksi, virusnog su podrijetla i tek zanemarivi udio tih slučajeva (tj. 0,5 - 2 %) razvije se u bakterijsku infekciju (Gwaltney 1996).
The later ones (starting with norfloxacin) possess an increasingly broader spectrum of activity; they are fluorinated at C-6 carbon of their basic ring structure, hence so-called fluoroquinolones. 
Kasnije tvari (počevši s norfloksacinom) imaju sve veći spektar djelovanja, fluorirane su na ugljiku C6 svoje osnovne prstenaste strukture te se zbog toga nazivaju fluorokinoloni.
Furthermore, activity of ofloxacin against relevant pathogens is too limited to justify use in nosocomial pneumonia. 
Nadalje, djelovanje ofloksacina protiv relevantnih patogena previše je ograničeno kako bi opravdalo primjenu u nozokomijalnoj pneumoniji.
Recurrent UTIs are common among young, healthy women, even though they generally have anatomically and physiologically normal urinary tracts (Hooton 2001). 
Rekurentne infekcije urinarnog trakta česte se među mladim, zdravim ženama čak i ako je u njih urinarni trakt anatomski i fiziološki normalan (Hooton 2001.).
The pathogens associated with pyelonephritis consists mainly of E. coli (75% to 95%), with occasional other species of Enterobacteriaceae, such as P. mirabilis and K. pneumoniae, and of Staphylococci. 
Patogeni povezani s pijelonefritisom uglavnom su E. coli (od 75 % do 95 %), povremeno druge vrste Enterobacteriaceae, kao što su P. mirabilis i K. pneumoniae te Staphylococci.
Therefore fluoroquinolones should be reserved as a last line treatment in patients where other therapeutic options are not effective or not tolerated. 
Stoga primjena fluorokinolona treba ostati sačuvana kao posljednja linija liječenja u bolesnika u kojih druge terapijske opcije nisu djelotvorne ili ih bolesnici ne podnose.